Defining prostate cancer risk before prostate biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1408-1418

  Pal, Raj P ^a   Maitra, Neil U ^a   Mellon, J Kilian ^a   Khan, Masood A ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biopsy; Imaging; Prostate cancer; Serum; Urine

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACID PHOSPHATASE PROSTATE ISOENZYME; BRCA1 PROTEIN; BRCA2 PROTEIN; EARLY PROSTATE CANCER ANTIGEN; EARLY PROSTATE CANCER ANTIGEN 2; ENGRAILED 2; HPC1 PROTEIN; HUMAN GLANDULAR KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RIBONUCLEASE L; TISSUE KALLIKREIN; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHROMOSOME REARRANGEMENT; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; ETHNIC GROUP; EXTERNAL BEAM RADIOTHERAPY; FIRST DEGREE RELATIVE; FOLLOW UP; GENE DELETION; GENE FUSION; GENE LOCUS; GENE MUTATION; HUMAN; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY; IMAGING; PROSTATE CANCER; SERUM; URINE;

BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84886312148     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.05.012     Document Type: Review

References (138)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
2. Haker S.J., Mulkern R.V., Roebuck J.R., et al. Magnetic resonance guided prostate interventions. Tp Magn Reson Imaging 2005, 16:355-368.
3. Brewster D.H., Fraser L.A., Harris V., et al. Rising incidence of prostate cancer in Scotland: Increased risk or increased detection?. BJU Int 2000, 85:463-473.
4. Jack R.H., Davies E.A., Møller H. Testis and prostate cancer incidence in ethnic groups in south east England. Int J Androl 2007, 30:215-221.
5. Winter H., Cheng K.K., Cummins C., et al. Cancer incidence in the South Asian population of England (1990-92). Br J Cancer 1999, 79:645-654.
6. Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol 2002, 168:906-913.
7. Edwards S.M., Kote-Jarai Z., Meitz J., et al. Two percent of men with prostate cancer harbor germline mutation in the BRCA2 gene. Am J Hum Genet 2003, 72:1-12.
8. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94:1358-1365. Breast Cancer Linkage Consortium.
9. Simard J., Dumont M., Labuda D., et al. Prostate cancer susceptibility genes; lessons learned and challenges posed. Endocr Relat Cancer 2003, 10(2):225-259.
10. Rebbeck T.R., Walker A.H., Zeigler-Johnson C., et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2002, 111:398-400.
11. Kouprina N., Pavlicek A., Noskov V.N., et al. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005, 15:1477-1486.
12. Berry R., Schroeder J.J., French A.J., et al. Evidence for a prostate cancer susceptibility locus on chromosome 20. Am J Hum Genet 2000, 67:82-91.
13. Al Olama A.A., Kote-Jarai Z., Giles G.G., et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009, 41:1058-1060.
14. Kote-Jarai Z., Olama A.A., Giles G.G., et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011, 43:785-791.
15. Eeles R.A., Kote-Jarai Z., Al Olama A.A., et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009, 41:1116-1121.
16. Schumacher F.R., Berndt S.I., Siddiq A., et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011, 20:3867-3895.
17. Mitra A.V., Bancroft E.K., Barbachano Y., et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU Int 2011, 107:28-39.
18. Mistry K., Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003, 16:95-101.
19. Spigelman S.S., McNeal J.E., Freiha F.S., et al. Rectal examination in volume determination of carcinoma of the prostate: Clinical and anatomical correlations. J Urol 1986, 136:1228-1230.
20. Smith D.S., Catalona W.J. Inter-examiner variability of digital rectal examination in detecting prostate cancer. Urology 1995, 45:70-74.
21. Gosselaar C., Roobol M.J., Roemeling S., et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008, 54:581-588.
22. Gerber G.S., Chodak G.W. Routine screening for cancer of the prostate. J Natl Cancer Inst 1991, 83:329-335.
23. Okotie O.T., Roehl K.A., Han M., et al. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007, 70:1117-1120.
24. Philip J., Dutta Roy S., Ballal M., et al. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?. BJU Int 2005, 95:969-971.
25. Rönnberg L., Vihko P., Sajanti E., et al. Clomiphene citrate administration to normogonadotropic subfertile men: Blood hormone changes and activation of acid phosphatase in seminal fluid. Int J Androl 1981, 4:372-378.
26. Kutscher W., Wolbergs H. Prostataphosphatase. Ztschr Physiol. Chem 1935, 236-237.
27. Gutman E.B., Sproul E.E., Gutman A.B. Significance of increased phosphatase activity of bone at site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936, 28:485.
28. Moul J.W., Connelly R.R., Perahia B., et al. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 1998, 159:935-940.
29. Roach M., Lu J., Pilepich M.V., et al. Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials. J Urol 1999, 161:864-868.
30. Fang L.C., Dattoli M., Taira A., et al. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology 2008, 71:146-150.
31. Jöbsis A.C., De Vries G.P., Meijer A.E., et al. The immunohistochemical detection of prostatic acid phosphatase: Its possibilities and limitations in tumour histochemistry. Histochem J 1981, 13:961-973.
32. Sobin L.H., Hjermstad B.M., Sesterhenn I.A., et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer 1986, 58:136-138.
33. Svanholm H., Hørder M. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques. Scand J Urol Nephrol Suppl 1988, 107:65-70.
34. Lowe F.C., Trauzzi S.J. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 1993, 20:589-595.
35. Brenckman W.D., Lastinger L.B., Sedor F. Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer. JAMA 1981, 245:2501-2504. 26.
36. Heller J.E. Prostatic acid phosphatase: Its current clinical status. J Urol 1987, 137:1091-1103.
37. Schacht M.J., Garnett J.E., Grayhack J.T. Biochemical markers in prostatic cancer. Urol Clin North Am 1984, 11:253-267.
38. Oesterling J.E. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145:907-923.
39. Ercole C.J., Lange P.H., Mathisen M., et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987, 138:1181-1184.
40. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 8:909-916.
41. Lövgren J., Valtonen-André C., Marsal K., et al. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999, 20:348-355.
42. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324:1156-1161.
43. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of Organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270:948-954.
44. Thompson I., Pauler D.K., Goodman P.J. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl. J Med 2004, 350:2239-2246.
45. Gerstenbluth R.E., Seftel A.D., Hampel N., et al. The accuracy of the increased prostate specific antigen level (≥20 ng/ml.) in predicting prostate cancer: Is biopsy always required?. J Urol 2002, 168:1990-1993.
46. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003, 170:S21-S27.
47. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ±4.0 ng per milliliter. N Eng J Med 2004, 350:2239-2246.
48. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993, 18:860-864.
49. Djulbegovic M., Beyth R.J., Neuberger M.M., et al. Screening for prostate cancer: Systematic review and meta-analysis of randomized controlled trials. BMJ 2010, 14:341. c4543.
50. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 26:1320-1328.
51. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
52. Hugosson J., Carlsson S., Aus G., et al. Mortality results from the Göteborg randomized population-based prostate cancer screening trial. Lancet Oncol 2010, 11:725-732. Aus G et l.
53. Loeb S., Vonesh E., Metter J., et al. What is the true number needed to screen and treat to save one life with prostate specific antigen testing. J Clin Oncol 2011, 29:464-467.
54. Lilja H., Ulmert D., Björk T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007, 25:431-436.
55. Ulmert D., Cronin A.M., Bjork T., et al. Prostate-specific antigen at or before 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study. BMC Med 2008, 15:6. 6.
56. Vickers A.J., Cronin A.M., Björk T., et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study. BMJ 2010, 14:c4521.
57. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991, 51:222-226.
58. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274:1214-1220.
59. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
60. Khan M.A., Partin A.W., Rittenhouse H.G., et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003, 170:723-726.
61. Luderer A.A., Chen Y.T., Soriano T.F., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995, 46:187-194.
62. Piironen T., Pettersson K., Suonpää M., et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996, 48(S):81-87.
63. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis. Eur Urol 2005, 48:386-399.
64. Benson M.C., Whang I.S., Pantuck A., et al. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992, 147:815-816.
65. Catalona W.J., Richie J.P., deKernion J.B., et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 1994, 152:2031-2036.
66. Kalish J., Cooner W.H., Graham S.D. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994, 43:601-606.
67. Giannarini G., Scott C.A., Moro U., et al. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?. Urol Oncol 2008, 26:353-360.
68. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267:2215-2220.
69. Vickers A.J., Savage C., O'Brien M.F., et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009, 27:398-403.
70. Ulmert D., Serio A.M., O'Brien M.F., et al. Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008, 20:835-841.
71. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000, 60:756-759.
72. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
73. Sokoll L.J., Sanda M.G., Feng Z., et al. A prospective, multicenter, National Cancer Institute early detection research network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200.
74. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1998, 53:939-944.
75. Lintula S., Stenman J., Bjartell A., et al. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005, 63:324-329.
76. Vickers A.J., Gupta A., Savage C.J., et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011, 20:255-261.
77. Partin A.W., Catalona W.J., Finlay J.A., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology 1999, 54:839-845.
78. Nam R.K., Diamandis E.P., Toi A., et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000, 18:1036-1042.
79. Haese A., Graefen M., Steuber T., et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003, 170:2269-2273.
80. Steuber T., Vickers A.J., Haese A., et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006, 118:1234-1240.
81. Xu J., Stolk J.A., Zhang X., et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000, 60:1677-1682.
82. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002, 287:1662-1670.
83. Jiang Z., Wu C.L., Woda B.A., et al. alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker. Histopathology 2000, 45:218-225.
84. Rubin M.A., Bismar T.A., Andrén O., et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005, 14:1424-1432.
85. Sreekumar A., Laxman B., Rhodes D.R., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004, 96:834-843.
86. Getzenberg R.H., Pienta K.J., Huang E.Y., et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991, 51:6514-6520.
87. Dhir R., Vietmeier B., Arlotti J., et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004, 171:1419-1423.
88. Paul B., Dhir R., Landsittel D., et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005, 65:4097-4100.
89. Leman E.S., Cannon G.W., Trock B.J., et al. EPCA-2: A highly specific serum marker for prostate cancer. Urology 2007, 69:714-720.
90. Leman E.S., Magheli A., Cannon G.W., et al. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate 2009, 69:1188-1194.
91. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59:5975-5979.
92. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002, 62:2695-2698.
93. Hessels D., Klein Gunnewiek J.M., van Oort I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003, 44:8-15. Discussion 15.
94. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008, 54:1081-1088.
95. Sokoll L.J., Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008, 389:1-6.
96. van Gils M.P., Hessels D., van Hooij O., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007, 13:939-943.
97. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69:532-535.
98. Deras I.L., Aubin S.M., Blase A., et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
99. Whitman E.J., Groskopf J., Ali A., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008, 180:1975-1978. Discussion 1978.
100. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 2008, 179:1804.
101. Roobol M.J., Schröder F.H., van Leeuwen P., et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010, 58:475-481.
102. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
103. Clark J., Merson S., Jhavar S., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
104. Scheble V.J., Braun M., Beroukhim R., et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010, 23:1061-1067.
105. Tomlins S.A., Aubin A.M., Urine S.J. ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA 2. Sci Transl Med 2011, 3. 94ra72.
106. Hessels D., Smit F.P., Verhaegh G.W., et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13:5103-5108.
107. Laxman B., Morris D.S., Yu J., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008, 68:645-649.
108. Salami S.S., Schmidt F., Laxman B., et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011, 19. PMID: 19664128.
109. Rostad K., Hellwinkel O.J., Haukaas S.A., et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009, 117:575-582.
110. Bose S.K., Bullard R.S., Donald C.D. Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth and survival. Transl Oncogenomics 2008, 3:37-43. survival.
111. Morgan R., Boxall A., Bhatt A., et al. Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011, 17:1090-1098.
112. Zielie P.J., Mobley J.A., Ebb R.G., et al. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme A racemase in prostatic secretions. J Urol 2004, 172:1130-1133.
113. Rogers C.G., Yan G., Zha S., et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J Urol 2004, 172:1501-1503.
114. Beyersdorff D., Taymoorian K., Knösel T., et al. MRI of prostate cancer at 1.5 and 3.0 T: Comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 2005, 185:1214-1220.
115. Fütterer J.J., Heijmink S.W., Scheenen T.W., et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006, 241:449-458.
116. Ogura K., Maekawa S., Okubo K., et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: Correlation with histopathologic results. Urology 2001, 57:721-726.
117. Hara N., Okuizumi M., Koike H., et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005, 62:140-147.
118. Szafer A., Zhong J., Gore J.C. Theoretical model for water diffusion in tissues. Magn Reson Med 1995, 33:697-712.
119. Desouza N.M., Reinsberg S.A., Scurr E.D., et al. Magnetic resonance imaging in prostate cancer: The value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 2007, 80:90-95.
120. Shimofusa R., Fujimoto H., Akamata H., et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005, 29:149-153.
121. Jung J.A., Coakley F.V., Vigneron D.B., et al. Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system. Radiology 2004, 233:701-708.
122. Heerschap A., Jager G.J., van der Graaf M., et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997, 17:1455-1460.
123. Vilanova J.C., Comet J., Barcelo-Vidal C., et al. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: Detection with MR imaging and MR spectroscopy. J Radiol 2009, 253:135-143.
124. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000, 164:400-404.
125. Umbehr M., Bachmann L.M., Held U., et al. Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol 2009, 55:575-590.
126. Kumar V., Jagannathan N.R., Kumar R., et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007, 20(1):11-20.
127. Sciarra A., Panebianco V., Ciccariello M., et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010, 16:1875-1883.
128. Tanimoto A., Nakashima J., Kohno H., et al. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007, 25:146-152.
129. Chen Y.J., Pu Y.S., Chueh S.C., et al. Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection. J Magn Reson Imaging 2011, 33:356-363.
130. Watanabe H., Kato H., Kato T., et al. Diagnostic application of ultrasonotomography to the prostate. Nihon Hinyokika Gakkai Zasshi 1968, 59:273-279.
131. Watanabe H., Date S., Ohe H., et al. A survey of 3,000 examinations by transrectal ultrasonotomography. Prostate 1980, 1:271-278.
132. Rifkin M.D., Dähnert W., Kurtz A.B. State of the art: Endorectal sonography of the prostate gland. AJR Am J Roentgenol 1990, 154:691-700.
133. Pinto F., Totaro A., Calarco A., et al. Imaging in prostate cancer: Present role and future perspectives. Urol Int 2011, 86:373-382.
134. Steuber T., Vickers A., Haese A., et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007, 120:1499-1504.
135. Fujita K., Ewing C.M., Chan D.Y., et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 2009, 124:664-669.
136. Whitaker H.C., Kote-Jarai Z., Ross-Adams H., et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 2010, 5:e13363.
137. Shariat S.F., Karam J.A., Walz J., et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008, 14:3785-3791.
138. Shariat S.F., Park S., Trinh Q.D., et al. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J Urol 2007, 178:1229-1236.